$5.93
11.89% yesterday
Nasdaq, Jul 09, 10:00 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$5.93
+0.50 9.21% 1M
-6.55 52.48% 6M
-1.41 19.21% YTD
-2.44 29.15% 1Y
-24.16 80.29% 3Y
-41.27 87.44% 5Y
+2.24 60.70% 10Y
+2.24 60.70% 20Y
Nasdaq, Closing price Wed, Jul 09 2025
+0.63 11.89%
ISIN
US92764N1028
Symbol
VIR
Sector
Industry

Key metrics

Basic
Market capitalization
$732.7m
Enterprise Value
$-69.0m
Net debt
positive
Cash
$801.7m
Shares outstanding
138.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
35.1 | 44.3
EV/Sales
negative | negative
EV/FCF
0.2
P/B
0.7
Financial Health
Equity Ratio
82.2%
Return on Equity
-45.4%
ROCE
-52.3%
ROIC
-129.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.9m | $16.5m
EBITDA
$-598.7m | $-530.9m
EBIT
$-611.6m | $-512.3m
Net Income
$-577.7m | $-446.6m
Free Cash Flow
$-422.1m
Growth (TTM | estimate)
Revenue
-73.8% | -77.7%
EBITDA
0.7% | 3.8%
EBIT
1.5% | 7.2%
Net Income
-7.1% | 14.4%
Free Cash Flow
45.8%
Margin (TTM | estimate)
Gross
96.2%
EBITDA
-2,869.9% | -3,210.3%
EBIT
-2,931.8%
Net
-2,769.0% | -2,700.6%
Free Cash Flow
-2,023.6%
More
EPS
$-4.2
FCF per Share
$-3.1
Short interest
13.3%
Employees
408
Rev per Employee
$180.0k
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Vir Biotechnology Inc forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
77%
Hold
23%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
21 21
74% 74%
100%
- Direct Costs 0.79 0.79
8% 8%
4%
20 20
74% 74%
96%
- Selling and Administrative Expenses 107 107
36% 36%
511%
- Research and Development Expense 525 525
1% 1%
2,517%
-599 -599
1% 1%
-2,870%
- Depreciation and Amortization 13 13
28% 28%
62%
EBIT (Operating Income) EBIT -612 -612
2% 2%
-2,932%
Net Profit -578 -578
7% 7%
-2,769%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Business Wire
about one month ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available und...
Neutral
Business Wire
about 2 months ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. ...
Neutral
Business Wire
about 2 months ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Event...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 408
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today